Bharat Biotech
-
Chhattisgarh health minister opposes use of Covaxin
India | Jan 10, 2021, 08:10 AM ISTChhattisgarh Health Minister TS Singh Deo on Saturday said the use of COVID-19 vaccine `Covaxin' must not be allowed in the state as its third-phase trial data has not been published yet.
-
Bharat Biotech to begin Phase-1 trials of its intranasal vaccine for COVID-19 in February-March
India | Jan 08, 2021, 12:17 PM ISTBesides Covaxin, Bharat Biotech has been actively working on developing another vaccine, for which it tied up with Washington University School of Medicine in St Louis for the novel "chimp-adenovirus" (Chimpanzee adenovirus), a single dose in tranasal vaccine for COVID-19.
-
We are global company, don't accuse us of inexperience: Bharat Biotech strong message to critics
News | Jan 04, 2021, 07:17 PM ISTThe chairman of Bharat Biotech - whose coronavirus vaccine Covaxin was yesterday given 'restricted use in emergency situation in public interest' - hit out today at critics querying the lack of Phase III trial data and others questioning the drug's efficacy.
-
Bharat Biotech slams criticism of indigenous vaccine Covaxin; we are a global company, says CMD
India | Jan 04, 2021, 11:02 PM ISTSpeaking during a virtual press conference, Bharat Biotech MD Krishna Ella sought to clear all doubts over the much awaited vaccine against coronavirus and asserted that he has no political connections.
-
Bharat Biotech's Covaxin cleared for conducting clinical trials on children
India | Jan 04, 2021, 02:38 PM ISTThe Drugs Controller General of India (DCGI) has given licensing permission to Hyderabad-based Bharat Biotech to manufacture 'Covaxin' for sale and distribution. The DCGI approval document said the firm can vaccinate children above the age of 12 years during the clinical trial mode.
-
Is it safe for cancer, diabetic patients to take COVID-19 vaccine? Details here
India | Jan 04, 2021, 10:50 AM ISTThe Serum Institute of India, the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield, while Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
-
500-600 Covid centres in phase 1 of vaccination: Delhi govt
India | Jan 03, 2021, 10:14 PM ISTDelhi Health Minister Satyendar Jain made the announcement during a press conference while commenting on the protocol that will be followed for the rollout of the vaccine.
-
Bharat Biotech gets licensing permission to manufacture Covaxin
India | Jan 03, 2021, 09:24 PM ISTThe Central Licensing Authority on Sunday granted permission to Bharat Biotech to manufacture Covaxin for sale and distribution, hours after the Drug Controller General of India (DCGI) approved the coronavirus vaccine for restricted emergency use.
-
Covaxin generated excellent safety data, says Bharat Biotech
India | Jan 03, 2021, 08:48 PM ISTBharat Biotech claimed on Sunday that its vaccine generated excellent safety data with robust immune responses to multiple viral proteins that persist.
-
Giant leap for innovation: Bharat Biotech after DCGI approval to Covaxin
India | Jan 03, 2021, 03:00 PM ISTBharat Biotech on Sunday said the DCGI approval for its COVID-19 vaccine Covaxin is a giant leap for novel product development in the country. Earlier in the day, the Drug Controller General of India (DCGI) approved Oxford-AstraZeneca vaccine Covishield, manufactured by the Serum Institute of India, and Bharat Biotech's Covaxin for restricted emergency use.
-
'Absolute rubbish': DCGI on impotency rumours, says Covid vaccines 110% safe
India | Jan 03, 2021, 01:17 PM ISTAs India gears up for the world's largest vaccination programme, the Drugs Controller General of India (DCGI) on Sunday quelled rumours surrounding the COVID-19 vaccines regarding impotency, rubbishing such speculations as "absolute nonsense".
-
Covishield, Covaxin get govt's nod: DCGI's Full Statement
India | Jan 03, 2021, 12:07 PM ISTThe expert panel has recommended granting permission for restricted emergency use of 'Covaxin' in "public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains.
-
Bharat Biotech recruits 23,000 volunteers for Phase III trials of Covaxin
India | Jan 02, 2021, 10:41 PM ISTBharat Biotech on Saturday announced successful recruitment of 23,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for phase-III clinical trial of its coronavirus vaccine 'Covaxin' across multiple sites in India.
-
COVAXIN, India's indigenously developed Covid vaccine recommended for restricted emergency use
News | Jan 02, 2021, 11:49 PM ISTAn expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine — Covaxin.
-
Covid-19 vaccines: Expert panel to meet today to review data on Serum Institute, Bharat Biotech
News | Jan 01, 2021, 12:02 PM ISTThe subject expert committee (SEC) of the national drugs regulator will meet again on Friday to take a decision on the emergency-use authorisation (EUA) application of Serum Institute of India’s (SII) Oxford-AstraZeneca and Bharat Biotech’s vaccine candidates against Coronavirus disease (Covid-19).
-
No emergency approval for vaccine maker SII, Bharat Biotech yet | What we know
India | Dec 30, 2020, 11:15 PM ISTThe analysis of the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech is still being conducted by regulator Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee and their next meeting will be held on January 1.
-
Covaxin can work against mutated coronavirus: Bharat Biotech
India | Dec 29, 2020, 08:00 PM ISTCovaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman andManaging Director of the city-based vaccine maker Krishna Ella said on Tuesday.
-
Bharat Biotech, maker of Covaxin, applies for emergency approval, again
India | Dec 23, 2020, 10:57 PM ISTHyderabad-based Bharat Biotech, which is developing the country's indigenous coronavirus vaccine in collaboration with the Indian Council of Medical Research, on Wednesday again applied to the Drug Controller General of India for the emergency use authorisation.
-
Bharat Biotech's Covaxin shows encouraging results in clinical trials
India | Dec 23, 2020, 10:40 PM ISTCovaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials.
-
Who should take coronavirus vaccine? Bharat Biotech's Chairman answers
India | Dec 23, 2020, 07:54 PM ISTBharat Biotech is developing Indian own vaccine for coronavirus called Covaxin. Its chairman was speaking in a virtual session on 'Sero surveillance significance in immunogenicity and safety in pre and post vaccination era' organised by industry body CII.